Combipack of Sitagliptin Phosphate and Metformin HCI SR

Combipack of sitagliptin phosphate (100mg) & Metformin HCI SR (1000mg)
GLISITAPTIN M KIT

Managing type 2 diabetes effectively often requires a combination of medications targeting different aspects of the disease. The Glisitaptin M Kit is a highly effective combipack that combines two potent antidiabetic agents: Sitagliptin Phosphate (100 mg) and Metformin HCl SR (1000 mg). This dual-therapy approach is designed to provide improved glycemic control for patients with type 2 diabetes mellitus (T2DM).

Key Composition and Mechanism of Action

1. Sitagliptin Phosphate (100 mg)

Sitagliptin is a DPP-4 inhibitor (Dipeptidyl Peptidase-4 inhibitor). It works by increasing the levels of incretin hormones, which:

• Enhance insulin secretion in response to meals.
• Reduce glucagon secretion, thereby decreasing hepatic glucose production.

By modulating these pathways, sitagliptin helps achieve better postprandial and fasting glucose levels.

2. Metformin HCl SR (1000 mg)

Metformin, a cornerstone in diabetes management, belongs to the biguanide class. The Sustained Release (SR) formulation ensures gradual release, minimizing gastrointestinal side effects. It works by:

• Reducing hepatic glucose production.
• Enhancing peripheral glucose uptake and utilization.
• Improving insulin sensitivity.

This dual mechanism addresses both the insulin resistance and overproduction of glucose characteristic of T2DM.

Why Choose Glisitaptin M Kit?

1. Enhanced Glycemic Control

   • The complementary mechanisms of sitagliptin and metformin provide superior glycemic control compared to monotherapy.
   • Targets both fasting and postprandial blood glucose.

2. Convenient Combipack

   • Simplifies treatment regimens, improving patient compliance.
   • Reduces pill burden, especially beneficial for patients requiring multiple medications.

3. Weight Neutrality

   • Unlike some other antidiabetic drugs, this combination is weight-neutral, making it a preferred choice for overweight or obese patients.

4. Low Risk of Hypoglycemia

   • Sitagliptin enhances insulin release only in response to meals, minimizing the risk of hypoglycemia.
   • Metformin alone is also associated with a low risk of hypoglycemia.

5. Improved Tolerability

   • The sustained-release formulation of metformin ensures reduced gastrointestinal discomfort.

Clinical Indications

The Glisitaptin M Kit is indicated for patients with type 2 diabetes who require:

• Better glycemic control not achieved with monotherapy.
• A combination therapy as part of their initial treatment regimen.

It is particularly suitable for individuals with:

• Poor fasting glucose levels.
• Elevated HbA1c.
• Minimal risk tolerance for hypoglycemia.

Dosage and Administration

• Recommended Dosage: One combipack daily with meals or as prescribed by a healthcare professional.
• Regular blood sugar monitoring is essential to avoid potential complications.
• Dose adjustments may be necessary based on kidney function, liver function, or other medical conditions.

Precautions and Contraindications

• Not suitable for patients with severe renal impairment or liver dysfunction.
• Avoid in cases of metabolic acidosis or a history of lactic acidosis.
• Caution is advised in elderly patients or those with predisposing conditions to hypoglycemia.

Side Effects

While generally well-tolerated, some patients may experience:

• Gastrointestinal symptoms like nausea or diarrhea (common with metformin).
• Upper respiratory tract infections or headache (occasionally reported with sitagliptin).

Severe side effects like lactic acidosis (rare but serious) or pancreatitis require immediate medical attention.

Conclusion

The Glisitaptin M Kit offers an efficient, well-tolerated, and comprehensive solution for the management of type 2 diabetes. Its unique combination of Sitagliptin Phosphate (100 mg) and Metformin HCl SR (1000 mg) addresses the multifaceted nature of diabetes while ensuring patient convenience and compliance. With proper medical supervision, this combipack can help patients achieve their glycemic targets and lead healthier lives. Steris Healthcare Pvt Ltd, operating as Sterispharma since its founding by expert professionals in the pharmaceutical industry in February 2018, is based in Navi Mumbai. The company is certified by WHO, GMP, and ISO, emphasizing its commitment to quality and safety. Sterispharma focuses on providing high-quality drugs at affordable prices throughout India, adhering strictly to WHO guidelines. Offering the convenience of an online pharmacy, customers can easily purchase medicines with home delivery options available. Sterispharma's mission is to supply a broad range of healthcare products to meet the diverse needs of the medical community. From advanced treatments and medications for rare conditions to essential health necessities, Sterispharma aims to serve the extensive demands of the healthcare industry. You can order medicines from Sterispharma through their websites, Sterisonline  ,  Sterisindia and Sterispharma. Their extensive product lineup includes treatments for Cardiology, Asthma, Respiratory Issues, Nasal Conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/Antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. 

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 7877551268, 7849827488

BUY NOW